Skip to content
Catalyst

all-cis-5,8,11,14,17-icosapentaenoic acidFinding

All-cis‑5,8,11,14,17-icosapentaenoic acid has no detected effect on interleukin‑6 concentration

no difference foundModerate evidenceFinding

01 · The sentence it was drawn from

“IPE did not cause significant changes in ICAM-1 or IL-6 levels.”
Quoted verbatim from Icosapent ethyl, a pure ethyl ester of eicosapentaenoic acid: effects on circulating markers of inflammation from the MARINE and ANCHOR studies.
This finding among the 81 findings on its endpoint

all-cis-5,8,11,14,17-icosapentaenoic acid

Interleukin-6 concentration

no difference found

Who
Adults with hypertriglyceridemia from two phase III trials reported together: MARINE (triglycerides 500 to 2000 mg/dL) and ANCHOR (triglycerides 200 to 499 mg/dL, all on statin therapy with controlled LDL-C); both IPE doses
Dose studied
icosapent ethyl (purified EPA ethyl ester) 4 g/day and 2 g/day for 12 weeks, versus matched placebo

Moderate evidencePMID 23325450 · 2013

02 · The study

Study
RCT
Duration
3 months

Evidence, by strength

  • strong
  • moderatethis finding
  • limited
  • very limited
  • insufficient

03 · The paper

American journal of cardiovascular drugs
What else it reported2 findings · 1 compound · 2 endpoints

04 · To cite this finding

This address does not change

https://catalystproject.ai/e/01M6ZDNBFH2XHTFRW754YX7WM8